Can bone markers predict survival in lung cancer patients?

NCT ID NCT02810262

Completed Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study enrolled 200 adults with lung adenocarcinoma that has spread to the bones. Researchers took bone biopsies, scans, and blood tests to measure bone and metabolic markers. The goal is to see if these markers are linked to how long patients live. This is an observational study, so it does not test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors better predict survival and guide treatment decisions for lung cancer that has spread to the bones.
What could go wrong: This is an observational study, not a treatment trial. It only looks for associations, so it won't directly improve outcomes. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA LUNG CANCER WITH BONE METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung adenocarcinoma lung cancer lung neoplasm metastatic carcinoma in the bone

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BONE METASTASES LUNG CANCER

Contacts and locations

Locations

Hospices Civils de Lyon - Hôpital Edouard Herriot - Centre des Métastases Osseuses (CEMOS)

Lyon, 69003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.